FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lucette Garreau

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Brain

Procedures

Concepts & Ideas

Tissue Distribution

Co-author Network

Publications

TOP 3
Sylvie Mavel; Johnny Vercouillie; Lucette Garreau; Tiziana Raguza; Aina Westrheim Ravna; Sylvie Chalon; Denis Guilloteau; Patrick Emond
Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.
Gaëlle Bouchez; Luc Sensebé; Patrick Vourc'h; Lucette Garreau; Sylvie Bodard; Angélique Rico; Denis Guilloteau; Pierre Charbord; Jean-Claude Besnard; Sylvie Chalon
Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Satish K Chitneni; Lucette Garreau; Bernard J Cleynhens; Nele Evens; Marva Bex; Peter Vermaelen; Sylvie Chalon; Roger Busson; Denis Guilloteau; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lucette Garreau (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Sylvie Mavel; Johnny Vercouillie; Lucette Garreau; Tiziana Raguza; Aina Westrheim Ravna; Sylvie Chalon; Denis Guilloteau; Patrick Emond
Docking study, synthesis, and in vitro evaluation of fluoro-MADAM derivatives as SERT ligands for PET imaging.
Bioorganic & medicinal chemistry 2008;16(19):9050-5.
2008: Gaëlle Bouchez; Luc Sensebé; Patrick Vourc'h; Lucette Garreau; Sylvie Bodard; Angélique Rico; Denis Guilloteau; Pierre Charbord; Jean-Claude Besnard; Sylvie Chalon
Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Neurochemistry international 2008;52(7):1332-42.
2008: Satish K Chitneni; Lucette Garreau; Bernard J Cleynhens; Nele Evens; Marva Bex; Peter Vermaelen; Sylvie Chalon; Roger Busson; Denis Guilloteau; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Improved synthesis and metabolic stability analysis of the dopamine transporter ligand [(18)F]FECT.
Nuclear medicine and biology 2008;35(1):75-82.
2007: Nicolas Giboureau; Patrick Emond; Roger R Fulton; David J Henderson; Sylvie Chalon; Lucette Garreau; Peter Roselt; Stefan Eberl; Sylvie Mavel; Sylvie Bodard; Michael J Fulham; Denis Guilloteau; Michael Kassiou
Ex vivo and in vivo evaluation of (2R,3R)-5-[(18)F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter.
Synapse (New York, N.Y.) 2007;61(12):962-70.
2007: Patrick Emond; Sylvie Mavel; Yolanda Zea-Ponce; Michael Kassiou; Lucette Garreau; Sylvie Bodard; Marie-Laure Drossard; Sylvie Chalon; Denis Guilloteau
(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter.
Nuclear medicine and biology 2007;34(8):967-71.
2006: Sylvie Chalon; Håkan Hall; Wadad Saba; Lucette Garreau; Frédéric Dollé; Christer Halldin; Patrick Emond; Michel Bottlaender; Jean-Bernard Deloye; Julie Helfenbein; Jean-Claude Madelmont; Sylvie Bodard; Zoïa Mincheva; Jean-Claude Besnard; Denis Guilloteau
Pharmacological characterization of (E)-N-(4-fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a highly promising fluorinated ligand for the dopamine transporter.
The Journal of pharmacology and experimental therapeutics 2006;317(1):147-52.
2004: Sylvie Chalon; Cécile Bronquard; Johnny Vercouillie; Ercem Kodas; Lucette Garreau; Sylvie Bodard; Patrick Emond; Jean-Claude Besnard; Denis Guilloteau
ADAM is an effective tool for in vivo study of serotonergic function: validation in rat models.
Synapse (New York, N.Y.) 2004;52(2):136-42.
2003: Sylvie Chalon; Jari Tarkiainen; Lucette Garreau; Håkan Hall; Patrick Emond; Johnny Vercouillie; Lars Farde; Philippe Dasse; Katarina Varnas; Jean-Claude Besnard; Christer Halldin; Denis Guilloteau
Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity.
The Journal of pharmacology and experimental therapeutics 2003;304(1):81-7.
2002: Johan Sandell; Meixiang Yu; Patrick Emond; Lucette Garreau; Sylvie Chalon; Kjell Någren; Denis Guilloteau; Christer Halldin
Synthesis, radiolabeling and preliminary biological evaluation of radiolabeled 5-methyl-6-nitroquipazine, a potential radioligand for the serotonin transporter.
Bioorganic & medicinal chemistry letters 2002;12(24):3611-3.
2002: Stéphanie Barc; Guylène Page; Laurence Barrier; Lucette Garreau; Denis Guilloteau; Bernard Fauconneau; Sylvie Chalon
Relevance of different striatal markers in assessment of the MPP+-induced dopaminergic nigrostriatal injury in rat.
Journal of neurochemistry 2002;80(3):365-74.
2001: Patrick Emond; Julie Helfenbein; Sylvie Chalon; Lucette Garreau; Johnny Vercouillie; Yves Frangin; Jean-Claude Besnard; Denis Guilloteau
Synthesis of tropane and nortropane analogues with phenyl substitutions as serotonin transporter ligands.
Bioorganic & medicinal chemistry 2001;9(7):1849-55.
2000: Luc Zimmer; Ercem Kodas; Denis Guilloteau; Lucette Garreau; Jean-Claude Besnard; Sylvie Chalon
Microdialysis as a tool for in vivo study of dopamine transporter function in rat brains.
Journal of neuroscience methods 2000;103(2):137-44.
1999: Sylvie Chalon; Lucette Garreau; Patrick Emond; Luc Zimmer; M P Vilar; Jean-Claude Besnard; Denis Guilloteau
Pharmacological characterization of (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-methylphenyl)n ortropane as a selective and potent inhibitor of the neuronal dopamine transporter.
The Journal of pharmacology and experimental therapeutics 1999;291(2):648-54.
1998: Denis Guilloteau; Patrick Emond; Jean-Louis Baulieu; Lucette Garreau; Yves Frangin; Léandre Pourcelot; L Mauclaire; Jean-Claude Besnard; Sylvie Chalon
Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2beta-carbomethoxy-3beta-(4'-m ethylph enyl)nortropane (PE2I).
Nuclear medicine and biology 1998;25(4):331-7.
1997: Lucette Garreau; Patrick Emond; Catherine Belzung; Denis Guilloteau; Yves Frangin; Jean-Claude Besnard; Sylvie Chalon
N-(3-lodoprop-2E-enyl)-2beta-carbomethoxy-3beta-(3',4'-dichloro phenyl)nortropane (beta-CDIT), a tropane derivative: pharmacological characterization as a specific ligand for the dopamine transporter in the rodent brain.
The Journal of pharmacology and experimental therapeutics 1997;282(1):467-74.
1997: Patrick Emond; Sylvie Chalon; Lucette Garreau; A M Dognon; Sylvie Bodard; Yves Frangin; Jean-Louis Baulieu; Jean-Claude Besnard; Denis Guilloteau
A new iodinated tropane derivative (beta-CDIT) for in vivo dopamine transporter exploration: comparison with beta-CIT.
Synapse (New York, N.Y.) 1997;26(1):72-80.
1997: Patrick Emond; Lucette Garreau; Sylvie Chalon; M Boazi; M Caillet; J Bricard; Yves Frangin; L Mauclaire; Jean-Claude Besnard; Denis Guilloteau
Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4'-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3',4'-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter.
Journal of medicinal chemistry 1997;40(9):1366-72.
1995: I Lena; J E Ombetta; Sylvie Chalon; A M Dognon; Jean-Louis Baulieu; Yves Frangin; Lucette Garreau; Jean-Claude Besnard; Denis Guilloteau
Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT.
Nuclear medicine and biology 1995;22(6):727-36.
1995: H Rafii; Sylvie Chalon; J E Ombetta; Yves Frangin; Lucette Garreau; A M Dognon; I Lena; Sylvie Bodard; M P Vilar; Jean-Claude Besnard
Synthesis and characterization of [125I]N-(2-aminoethyl)-4-iodobenzamide as a selective monoamine oxidase B inhibitor.
Nuclear medicine and biology 1995;22(5):617-23.
1995: C Branger; Lucette Garreau; A M Dognon; Yves Frangin; M Caillet; J E Ombetta-Goka; Sylvie Chalon; Jean-Claude Besnard; Denis Guilloteau
Synthesis of 4'-iodo-5-methoxy-valerophenone O-(2-aminoethyl)oxime as an agent for exploration of serotoninergic transporter.
Nuclear medicine and biology 1995;22(2):157-64.
1992: C Foulon; Lucette Garreau; Sylvie Chalon; G Desplanches; Yves Frangin; Jean-Claude Besnard; Jean-Louis Baulieu; Denis Guilloteau
Synthesis and in vitro binding properties of halogenated analogues of GBR as new dopamine uptake carrier ligands.
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology 1992;19(5):597-600.